aBLA Filing Intelligence & Biosimilar Opportunity

Jemperli

Dostarlimab-Gxly

Anticancer

Injection Injectable

Approval Date

22-Apr-21

Data Exclusivity Expiry

22-Apr-25

Market Exclusivity Expiry

22-Apr-33

Commercial snapshot

Market performance & projections

Revenue ($M)

1135

CAGR (%)

0.1549

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1423

2027

1666

2028

1863

2029

2019

2030

2152

2031

2284

2032

2415

Molecule profile

Details & specifications

Molecule

Dostarlimab-Gxly

Innovator

GLAXOSMITHKLINE LLC

Dosage Form

Injection Injectable

Strength

500 mg/10 mL

Therapeutic Category

Anticancer

Usage

To treat endometrial cancer

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.